Physician profile
Allyn Mccarthy
NPI 1023793460
$184.06
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.13 · 2023: $43.11 · 2024: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $170.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $34.67 | 2024 | Rukobia, Apretude |
| Astrazeneca Pharmaceuticals LP | $27.83 | 2022-2023 | Fasenra |
| Merck Sharp & Dohme LLC | $27.72 | 2024 | Dificid, Delstrigo, Pifeltro |
| Verrica Pharmaceuticals INC. | $18.50 | 2024 | Ycanth |
| Antares Pharma, INC. | $17.67 | 2024 | Xyosted |
| Indivior INC. | $15.65 | 2024 | Sublocade |
| Idorsia Pharmaceuticals US INC | $14.83 | 2023 | Quviviq |
| Napo Pharmaceuticals INC | $13.61 | 2024 | Mytesi |
| Lilly USA, LLC | $13.58 | 2023 | Zepbound, Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyn Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.